Page last updated: 2024-08-24

ranolazine and Ventricular Fibrillation

ranolazine has been researched along with Ventricular Fibrillation in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (7.14)	29.6817
2010's	12 (85.71)	24.3611
2020's	1 (7.14)	2.80

Authors

Authors	Studies
Azam, MA; Kusha, M; Labos, C; Lai, PF; Massé, S; Nair, GK; Nanthakumar, K; Tan, NS; Zamiri, N	1
Bontempi, L; Cerini, M; Curnis, A; Giacopelli, D; Inama, L; Raweh, A; Salghetti, F; Sciatti, E; Vassanelli, F; Villa, C; Vizzardi, E	1
Aktas, MK; Alexis, JD; Ayala-Parades, F; Baranchuk, A; Beck, CA; Brown, MW; Daubert, JP; Dubuc, M; Feng, C; Haigney, M; Huang, DT; Mazur, A; McNitt, S; McPherson, CA; Mitchell, LB; Moss, AJ; Natale, A; Oakes, D; Piccini, JP; Pyykkonen, K; Raitt, M; Rashtian, MY; Schuger, C; Winters, S; Worley, SJ; Zareba, W; Ziv, O	1
Aidonidis, I; Dipla, K; Hatziefthimiou, A; Moschovidis, V; Simopoulos, V; Stamatiou, R; Stravela, S	1
Alberola, A; Brines, L; Calvo, C; Chorro, FJ; del Canto, I; Parra, G; Soler, C; Such, L; Such-Miquel, L; Tormos, Á; Trapero, I; Zarzoso, M	1
Bögeholz, N; Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Güner, F; Kochhäuser, S; Leitz, P; Pott, C	1
Belardinelli, L; Bhandari, A; Dhalla, AK; Dow, J; Kloner, RA; Shryock, JC; Wang, WQ	1
Acar, M; Belardinelli, L; Carvas, M; Nascimento, BC; Nearing, BD; Verrier, RL	1
Baez-Escudero, JL; Beshai, JF; Burke, MC; Shah, DP; Weisberg, IL	1
Belardinelli, L; Datti, IP; Nanbu, DY; Nearing, BD; Nieminen, T; Pegler, JR; Tavares, CA; Vaz, GR; Verrier, RL	1
Bhandari, A; Dow, JS; Kloner, RA	1
Karagueuzian, HS; Lee, JH; Morita, N; Qu, Z; Sovari, A; Weiss, JN; Xie, Y	1
Belardinelli, L; Breithardt, G; Eckardt, L; Frommeyer, G; Grundmann, F; Milberg, P; Osada, N; Rajamani, S; Stypmann, J	1
Belardinelli, L; Kumar, K; Nieminen, T; Verrier, RL	1

Reviews

1 review(s) available for ranolazine and Ventricular Fibrillation

Article	Year
Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2013, Volume: 15, Issue:3 Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Disease; Electrocardiography; Heart Conduction System; Heart Failure; Humans; Myocardial Ischemia; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Treatment Outcome; Ventricular Fibrillation	2013

Article

Year

Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2013, Volume: 15, Issue:3

Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Disease; Electrocardiography; Heart Conduction System; Heart Failure; Humans; Myocardial Ischemia; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Treatment Outcome; Ventricular Fibrillation

2013

Trials

1 trial(s) available for ranolazine and Ventricular Fibrillation

Article	Year
Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. Journal of the American College of Cardiology, 2018, 08-07, Volume: 72, Issue:6 Topics: Aged; Cardiovascular Agents; Defibrillators, Implantable; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Ranolazine; Risk Factors; Tachycardia, Ventricular; Ventricular Fibrillation	2018

Article

Year

Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.

Journal of the American College of Cardiology, 2018, 08-07, Volume: 72, Issue:6

Topics: Aged; Cardiovascular Agents; Defibrillators, Implantable; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Ranolazine; Risk Factors; Tachycardia, Ventricular; Ventricular Fibrillation

2018

Other Studies

12 other study(ies) available for ranolazine and Ventricular Fibrillation

Article	Year
Effects of Late Sodium Current Blockade on Ventricular Refibrillation in a Rabbit Model. Circulation. Arrhythmia and electrophysiology, 2017, Volume: 10, Issue:3 Topics: Animals; Calcium; Calcium Channels; Disease Models, Animal; Electric Countershock; Heart Arrest; Logistic Models; Pyridines; Rabbits; Random Allocation; Ranolazine; Reference Values; Sodium Channel Blockers; Sodium Channels; Statistics, Nonparametric; Triazoles; Ventricular Fibrillation	2017
Ranolazine therapy in drug-refractory ventricular arrhythmias. Journal of cardiovascular medicine (Hagerstown, Md.), 2017, Volume: 18, Issue:7 Topics: Aged; Anti-Arrhythmia Agents; Defibrillators, Implantable; Disease Progression; Drug Resistance; Electric Countershock; Female; Heart Failure; Humans; Male; Middle Aged; Ranolazine; Recurrence; Tachycardia, Ventricular; Time Factors; Treatment Outcome; Ventricular Fibrillation	2017
Dose-Dependent Effects of Ranolazine on Reentrant Ventricular Arrhythmias Induced After Subacute Myocardial Infarction in Rabbits. Journal of cardiovascular pharmacology and therapeutics, 2020, Volume: 25, Issue:1 Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heart Rate; Male; Myocardial Infarction; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Tachycardia, Ventricular; Time Factors; Ventricular Fibrillation	2020
Ranolazine Attenuates the Electrophysiological Effects of Myocardial Stretch in Langendorff-Perfused Rabbit Hearts. Cardiovascular drugs and therapy, 2015, Volume: 29, Issue:3 Topics: Animals; Biomechanical Phenomena; Electrophysiological Phenomena; Heart; In Vitro Techniques; Isolated Heart Preparation; Rabbits; Ranolazine; Ventricular Fibrillation	2015
Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome. Journal of cardiovascular electrophysiology, 2016, Volume: 27, Issue:10 Topics: Action Potentials; Animals; Anisoles; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Disease Models, Animal; Electrocardiography; Heart Rate; Isolated Heart Preparation; Pinacidil; Pyrrolidines; Rabbits; Ranolazine; Sodium Channel Blockers; Time Factors; Ventricular Fibrillation	2016
Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. American journal of physiology. Heart and circulatory physiology, 2009, Volume: 297, Issue:5 Topics: Acetanilides; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Rate; Infusions, Intravenous; Injections, Intravenous; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Time Factors; Ventricular Fibrillation	2009
Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart. Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:3 Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Disease Models, Animal; Female; Injections; Male; Piperazines; Ranolazine; Refractory Period, Electrophysiological; Swine; Time Factors; Ventricular Fibrillation	2010
Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8). Pacing and clinical electrophysiology : PACE, 2012, Volume: 35, Issue:3 Topics: Acetanilides; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Autistic Disorder; Drug Therapy, Combination; Humans; Long QT Syndrome; Male; Piperazines; Ranolazine; Syndactyly; Treatment Outcome; Ventricular Fibrillation; Verapamil	2012
Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model. Heart rhythm, 2011, Volume: 8, Issue:4 Topics: Acetanilides; Animals; Coronary Circulation; Coronary Stenosis; Disease Models, Animal; Electrophysiologic Techniques, Cardiac; Enzyme Inhibitors; Male; Piperazines; Ranolazine; Severity of Illness Index; Treatment Outcome; Ventricular Fibrillation	2011
First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. Journal of cardiovascular pharmacology and therapeutics, 2011, Volume: 16, Issue:2 Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Enzyme Inhibitors; Female; Infusions, Intravenous; Injections, Intravenous; Lidocaine; Myocardial Reperfusion Injury; Piperazines; Random Allocation; Ranolazine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sotalol; Statistics, Nonparametric; Tachycardia, Ventricular; Ventricular Fibrillation	2011
Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3 Topics: Acetanilides; Action Potentials; Animals; Male; Piperazines; Ranolazine; Rats; Rats, Inbred F344; Sodium Channel Blockers; Ventricular Fibrillation	2011
New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia. Journal of cardiac failure, 2012, Volume: 18, Issue:12 Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Heart Failure; Piperazines; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Sotalol; Ventricular Fibrillation	2012